1 October 2009: The third exercise period for Class A Warrants and Class B Warrants, issued in connection with the  rights issue registered 19 February 2009, was concluded yesterday. This was  the last opportunity for exercising Class A Warrants. In total 113 Class A Warrants and  zero Class B Warrants were exercised. As a consequence, a total of 113 new shares in NorDiag have been issued, each with a nominal value of NOK 1.00, at a subscription price of  NOK 5,00. The share capital of the Company will at the same  time be increased from NOK 12,065,169 to NOK 12,065,282, and the total number of shares in issue will increase from 12,065,169 to 12,065,282.

According to the resolution by the extraordinary general meeting 19 December 2008, the Class A Warrants and Class B Warrants that were issued in connection with the rights issue may only be exercised in the periods 15-31 March, 15-30 June, 15-30 September and/or 15-31 December. Class A Warrants was exercisable up to and including 30 September 2009, while Class B Warrants are exercisable up to and including 30 June 2010.

Contact:
CFO Tone Kvåle, phone +47 915 19576

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and tests), for sample preparation of bacterial and human DNA from difficult biological samples. DNA diagnostics give a more rapid and precise answer, and are the fastest growing market within diagnostics. The Company 's applications are today used in connection with STI, Tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Stockholm - Sweden, West Chester (PA) - USA and Vienna - Austria. The group has today 40,1 man years. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

For further information - www.nordiag.com.

Read the notice in Norwegian here